An interventional study of DCog Short in Neurotoxicity, Neurotoxicity Syndromes and Hematologic Malignancy, sponsored by Beth Israel Deaconess Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Neurotoxicity Syndromes with a site in United States — 6 open to participants now, 11 under way, 3 of them phase 3. Neurotoxicity Syndromes · United States.
Among the 76 studies in Neurotoxicity Syndromes with a site in United States, this one is the 32nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 74th registered.
133 studies on the registry are indexed under Neurotoxicity Syndromes; 17 are open to participants now.
Browse Neurotoxicity Syndromes studies →6 of the 76 studies in Neurotoxicity Syndromes with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Ka-Wai Ho · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Ellis Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Neurotoxicity Syndromes studies recruiting now, 11 (73%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 92 across 86 interventional studies indexed under Neurotoxicity Syndromes.
Median enrollment 85 across the 52 interventional studies, 76 across the 23 observational. Of the 61 that completed or were terminated, 28 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 76 have an industry lead sponsor. The 10 most frequent:
Beth Israel Deaconess Medical Center is the lead sponsor of 570 studies on the registry; 80 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 62 (82%) have results posted.
Beth Israel Deaconess Medical Center has 1 study filed under Neurotoxicity Syndromes — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurotoxicity Syndromes with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03089905Phase 3Murdoch Childrens Research InstituteA Study to Compare the Long-term Outcomes After Two Different Anaesthetics | 2026-12 |
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT06950190Phase 3Ellis MedicineEvaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) | 2027-02-20 |
| NCT06144151M.D. Anderson Cancer CenterA Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity | 2027-04-01 |
| NCT07767981University of ChicagoMicrobiome Determinants of Adverse Effects of Stereotactic Radiosurgery | 2027-08-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Neurotoxicity Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
The goal of this pilot study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy. This is the first time investigators are examining this tool.
The U.S. Food and Drug Administration (FDA) has not approved DCOG Short as a mobile application tool to evaluate neurotoxicity for hematologic malignancies.
The research study procedures include screening for eligibility, questionnaires, and cognitive assessments.
It is expected that about 40 people will take part in this research study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
40 enrolled participants will complete: * Baseline visit * Daily study visits during hospitalization, then via phone: 2x weekly on days 14 - 21, then weekly on days 21 - 30 * 90 Day follow up visit
Behavioral: DCog Short
An iPad-based cognitive assessment instrument to evaluate neurotoxicity and consisting of a series of tests that measure various aspects of cognitive function. After hospital discharge, participants will be provided with iPads which will be returned at the 90 day follow up visit.
Sensitivity of DCog Short for Early Detection of Neurotoxicity
Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to detect neurotoxicity on or before the onset of clinically confirmed ICANS. Sensitivity is defined as the proportion of patients with clinically confirmed ICANS for whom DCog Short indicates neurotoxicity on or before ICANS onset. DCog Short will be considered effective if sensitivity is ≥75% and non-promising if sensitivity is \<50%.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Specificity of DCog Short for Early Detection of Neurotoxicity
Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Specificity is defined as the proportion of patients who do not develop clinically confirmed ICANS and are not indicated by DCog Short. DCog Short will be considered effective if specificity is ≥75% and non-promising if specificity is \<50%.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Positive Predictive Value (PPV) of DCog Short for Early Detection of Neurotoxicity
Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Positive predictive value is defined as the proportion of patients indicated by DCog Short who subsequently develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) based on standard clinical assessment.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Negative Predictive Value (NPV) of DCog Short for Early Detection of Neurotoxicity
Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Negative predictive value is defined as the proportion of patients not indicated by DCog Short who do not develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) based on standard clinical assessment.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Raw Accuracy of DCog Short for Early Detection of Neurotoxicity
Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Raw accuracy is defined as the proportion of patients correctly classified by DCog Short, including both patients who develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and those who do not, based on standard clinical assessment.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Immune Effector Cell-Associated Encephalopathy (CARTOX-10) Score Change from Baseline
For ICANS detection and monitoring, the Immune Effector Cell-Associated Encephalopathy (ICE) score, also called CARTOX-10, will be used. The total score ranges from 0 to 10, with higher scores indicating normal cognitive function. Detailed scoring instructions and grading criteria are provided in Appendix A of the protocol.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Differences in Neurotoxicity Development and Detection Across CAR T-Cell Therapy Types
Neurotoxicity will be monitored using DCog Short and CARTOX-10 assessments throughout the study period. Immune Effector Cell-Associated Encephalopathy (ICE) score, e ranges from 0 to 10, with higher scores indicating normal cognitive function. Detailed scoring instructions and grading criteria are provided in Appendix A of the protocol.
Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Jul 2026 → Apr 2026, primary completion Aug 2026 → Sep 2027 and completion Aug 2027 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center →